Skip to main content

Table 2 Crude infection rates for each medication initiation cohort

From: The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis

Medication exposure Person-years of follow-up Number of infections Infection rate per 100 person-years (95 % CI)
MTX 2668.5 39 1.46 (1.07–2.00)
TNFi monotherapy 2144.0 33 1.54 (1.09–2.17)
TNFi + MTX combination 1094.5 19 1.74 (1.11–2.72)
Anakinra with or without MTX 225.9 19 8.41 (5.36–13.2)
MTX with SJIA 113.7 3 2.64 (0.85–8.18)
Etanercept 2594.0 37 1.43 (1.03–1.97)
Adalimumab 413.2 12 2.90 (1.65–5.11)
Infliximab 227.1 3 1.32 (0.43–4.10)
  1. MTX Methotrexate, TNFi Tumor necrosis factor inhibitor, SJIA Systemic juvenile idiopathic arthritis
\